SCHEMBL13627952

SCHEMBL13627952

N#Cc1ccccc1CN1C(=O)/C(=N\O)c2ccccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
MAPT P10636 3/20 0.41
TSHR P16473 3/20 0.41
LRRK2 Q5S007 1/20 0.41
PKM P14618 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
THRB P10828 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
GALR3 O60755 1/20 0.39
RAB9A P51151 1/20 0.39
NOX4 Q9NPH5 1/20 0.39
TGM2 P21980 1/20 0.39
COMT P21964 1/20 0.38
BRD4 O60885 1/20 0.38
CA12 O43570 2/20 0.38
CA2 P00918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627973 0.86 CHRM5 (0.47) ALDH1A1THRBNOX4CA12CA2
SCHEMBL18974296 0.82 TGM2 (0.57) ALDH1A1MAPTTSHRHSD17B10TGM2
SCHEMBL13627898 0.80 ALDH1A1 (0.50) ALDH1A1MAPTTSHRLRRK2PKM
SCHEMBL13627987 0.78 GRIN1 (0.38) ALDH1A1MAPTTSHRTHRBPOLB
SCHEMBL8736703 0.77 ALDH1A1 (0.54) ALDH1A1MAPTPKMNPSR1THRB
SCHEMBL7611051 0.76 ALDH1A1 (0.66) ALDH1A1MAPTTSHRLRRK2PKM
SCHEMBL7611054 0.76 ALDH1A1 (0.66) ALDH1A1MAPTTSHRLRRK2PKM
SCHEMBL13627997 0.76 GRIN1 (0.36) ALDH1A1MAPTGALR3RAB9ANOX4
SCHEMBL13627899 0.76 ACHE (0.56) ALDH1A1MAPTTSHRLRRK2PKM
SCHEMBL28500539 0.76 ALDH1A1 (0.38) ALDH1A1MAPTTSHRLRRK2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885MAPT 1666/4885TSHR 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.